Obsidian Therapeutics
  • About Us
    • Overview
    • Our Vision
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • Overview
    • Our Pipeline
    • cytoDRiVE® PLATFORM
    • Publications
    • Partners
  • Our Lead Clinical Program
    • Overview
    • For Patients
    • Expanded Access Policy
    • OBX-115
  • News
  • Join Our Team
    • Overview
    • Our Culture
    • Testimonials
    • Benefits
    • Job Postings
  • Contact

News

Back to News
Previous
Next
May 8, 2024

Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

CAMBRIDGE, Mass., May 8, 2024 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Dana Alexander as Chief Technical Officer.

“Dana has over two decades of operational expertise across cell therapy, gene therapy and biologics process development and chemistry, manufacturing, and controls (CMC), from Phase 1 through commercialization,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. “His leadership will be instrumental as we continue leveraging our proprietary cytoDRiVE® platform to advance our lead tumor-infiltrating lymphocyte (TIL) cell therapy, OBX-115, through clinical development for the treatment of solid tumors. We are delighted to welcome Dana to our management team.”

“I am thrilled to be joining the highly accomplished and passionate Obsidian leadership team and to have the opportunity to grow and expand the company’s CMC capabilities,” said Mr. Alexander. “I look forward to collaborating with the team to advance OBX-115 and maximizing the company’s platform for manufacturing patient-specific engineered cell and gene therapies as Obsidian’s pipeline expands.”

Mr. Alexander most recently served as Senior Vice President of Technical Operations at AlloVir, where he was responsible for building and leading all CMC technical functions including manufacturing, process and analytical development, supply chain, CMC program management and quality operations. Previously, Mr. Alexander held roles as Vice President of Operations, Viral Vector Services at Thermo Fisher Scientific (Brammer Bio) and Chief Operations Officer at Anika Therapeutics.  He also spent 14 years at Sanofi Genzyme in roles of increasing responsibility in CMC operations. Mr. Alexander holds an M.B.A. from Boston University and a B.S. in Chemical Engineering from Northeastern University.

 

About OBX-115

Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing clinical trials in advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) (NCT05470283 and NCT06060613).

 

About Obsidian Therapeutics

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.

 

Media:

david.rosen@argotpartners.com

212-600-1902

Back to News
Obsidian Therapeutics
  • About Us
  • Our Science
  • Our Lead Clinical Program
  • News
  • Join Our Team
  • Contact

Privacy // Terms of Use
© 2025 Obsidian Therapeutics, Inc. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Our Pipeline Job Postings
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. By continuing to navigate our website, you consent to the use of cookies, our privacy policy and terms of use.
Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT